Aaron Rosenberg
Hematology & Oncology · Sacramento, CANPI 1144479411
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,012 of the $55,124 with a category attached, or 61.7%. 20 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 33.7% of the total. Reporting peaked in 2019 at $24,049 and has fallen 68.3% since, to $7,622 in 2025.
Across 71 payments — averaging $776.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- Johnson & Johnson$11K
- Pfizer$8K
- Amgen$6K
- E.r. Squibb & Sons, L.L.C.$4K
- Sanofi$3K
- plus $4K from 14 others
Across 60 payments — averaging $18,456 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$489K
- Pfizer$376K
- GSK$113K
- Takeda Pharmaceuticals U.S.A., Inc.$47K
- Bristol Myers Squibb$47K
- Genentech, Inc.$29K
- plus $8K from 1 others
What the payments were for
- Consulting fees$12,51523%
- Speaking & faculty fees$34,01262%
- Travel & lodging$6,16211%
- Food & beverage$2,1944%
- Education$2400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $18,580 |
| Johnson & Johnson | 11 | $11,296 |
| Pfizer | 10 | $7,725 |
| Amgen | 7 | $6,106 |
| E.r. Squibb & Sons, L.L.C. | 4 | $4,162 |
| Sanofi | 3 | $2,883 |
| Seagen Inc. | 3 | $1,699 |
| Adaptive Biotechnologies Corporation | 1 | $1,200 |
| Bristol Myers Squibb | 6 | $682 |
| Secura Bio, Inc. | 1 | $184 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $125 |
| Sanofi-aventis U.S. LLC | 2 | $113 |
| AstraZeneca | 2 | $112 |
| Janssen Scientific Affairs, LLC | 1 | $73 |
| Beigene USA, Inc. | 2 | $67 |
| Abiomed | 1 | $44 |
| Gilead | 1 | $32 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Incyte Corporation | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,124 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 23 | $449,609 |
| PomalystPomalidomide | 14 | $315,595 |
| NinlaroIxazomib Citrate | 19 | $230,648 |
| Lenalidomide | 14 | $175,035 |
| CalquenceAcalabrutinib Maleate | 12 | $165,026 |
| VenclextaVenetoclax | 25 | $163,346 |
| CresembaIsavuconazonium Sulfate | 17 | $96,526 |
| ZarxioFilgrastim-Sndz | 29 | $94,231 |
| Plerixafor | 16 | $46,099 |
| XareltoRivaroxaban | 18 | $23,390 |
| EliquisApixaban | 12 | $13,217 |
| Dexamethasone | 91 | $1,504 |
| Acyclovir | 116 | $1,348 |
| Ondansetron Hcl | 55 | $665 |
| Prochlorperazine Maleate | 34 | $408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $682 | $449,60923 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $4,162 | $315,59514 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $18,580 | $230,64819 claims |
| AstraZenecaCalquence | $112 | $165,02612 claims |
| Johnson & JohnsonXarelto | $11,296 | $23,39018 claims |
| PfizerEliquis | $7,725 | $13,21712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Sacramento
- Nitin RohatgiSacramento$814K
- Mehrdad AbediSacramento$613K
- Adam GiermaszSacramento$438K
- Scott ChristensenSacramento$349K
- David GandaraSacramento$336K
- Joseph TuscanoSacramento$258K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.